| meta-analysis | Q815382 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/J.1468-1331.2011.03528.X |
| P953 | full work available at URL | https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1468-1331.2011.03528.x |
| https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1468-1331.2011.03528.x | ||
| P698 | PubMed publication ID | 21973313 |
| P2093 | author name string | P. P. Sfikakis | |
| D. D. Mitsikostas | |||
| E-M Delicha | |||
| L. I. Mantonakis | |||
| N. G. Chalarakis | |||
| P2860 | cites work | Developing and evaluating complex interventions: the new Medical Research Council guidance | Q24647443 |
| Bias in meta-analysis detected by a simple, graphical test | Q24685585 | ||
| Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement | Q27860606 | ||
| Quantifying heterogeneity in a meta-analysis | Q27860672 | ||
| Assessing the quality of reports of randomized clinical trials: is blinding necessary? | Q27860973 | ||
| Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II | Q28396036 | ||
| The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee | Q29618782 | ||
| When words are painful: unraveling the mechanisms of the nocebo effect | Q31106595 | ||
| Cortical correlates of false expectations during pain intensity judgments--a possible manifestation of placebo/nocebo cognitions | Q33214979 | ||
| Fibromyalgia: an overview | Q33517260 | ||
| Medically unexplained physical symptoms, anxiety, and depression: a meta-analytic review | Q33967381 | ||
| Nocebo is the enemy, not placebo. A meta-analysis of reported side effects after placebo treatment in headaches | Q34158126 | ||
| Conscious expectation and unconscious conditioning in analgesic, motor, and hormonal placebo/nocebo responses. | Q34199513 | ||
| Nonspecific medication side effects and the nocebo phenomenon | Q34519096 | ||
| The biochemical and neuroendocrine bases of the hyperalgesic nocebo effect. | Q34581978 | ||
| Scales to assess the quality of randomized controlled trials: a systematic review | Q34724144 | ||
| Placebo and nocebo effects are defined by opposite opioid and dopaminergic responses | Q34746177 | ||
| A functional magnetic resonance imaging study on the neural mechanisms of hyperalgesic nocebo effect | Q37113699 | ||
| Treating patients with fibromyalgia in primary care settings under routine medical practice: a claim database cost and burden of illness study | Q37206982 | ||
| New insights into the placebo and nocebo responses | Q37230629 | ||
| Interpretation of tests of heterogeneity and bias in meta-analysis | Q37329334 | ||
| A systematic review of adverse events in placebo groups of anti-migraine clinical trials | Q37603565 | ||
| The contributions of suggestion, desire, and expectation to placebo effects in irritable bowel syndrome patients | Q39390370 | ||
| Fibromyalgia syndrome and depressive symptoms: comorbidity and clinical correlates | Q39851636 | ||
| Epidemiology, costs, and the economic burden of fibromyalgia | Q42560782 | ||
| Prevalence of fibromyalgia: a survey in five European countries | Q43407868 | ||
| Placebo adverse events in headache trials: headache as an adverse event of placebo | Q44570003 | ||
| Placebo and Nocebo Responses, Cortisol, and Circulating Beta-Endorphin | Q44595395 | ||
| Placebo-associated blood pressure response and adverse effects in the treatment of hypertension: observations from a Department of Veterans Affairs Cooperative Study | Q45334592 | ||
| Nocebo effects in multiple sclerosis trials: a meta-analysis | Q46822234 | ||
| Predictors of adherence to treatment in women with fibromyalgia | Q51947988 | ||
| The role of learning in nocebo and placebo effects | Q51960960 | ||
| Pharmacotherapeutics in fibrositis | Q52077637 | ||
| Blockade of nocebo hyperalgesia by the cholecystokinin antagonist proglumide | Q73485107 | ||
| The nocebo reaction | Q79032458 | ||
| Medication adherence and healthcare costs among fibromyalgia patients treated with duloxetine | Q83101272 | ||
| The Combination of Estimates from Different Experiments | Q100745541 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | placebo | Q269829 |
| meta-analysis | Q815382 | ||
| nocebo | Q1332954 | ||
| fibromyalgia | Q540571 | ||
| P304 | page(s) | 672-680 | |
| P577 | publication date | 2011-10-04 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | European Journal of Neurology | Q15757256 |
| P1476 | title | Nocebo in fibromyalgia: meta-analysis of placebo-controlled clinical trials and implications for practice | |
| Nocebo in fibromyalgia: meta‐analysis of placebo‐controlled clinical trials and implications for practice | |||
| P478 | volume | 19 |
| Q36448998 | "This may hurt": predictions in procedural disclosure may do harm |
| Q38219326 | Adverse events of placebo-treated, drug-resistant, focal epileptic patients in randomized controlled trials: a systematic review. |
| Q38259757 | Characterization of the adverse events profile of placebo-treated patients in randomized controlled trials on drug-resistant focal epilepsies. |
| Q47555962 | Clinical relevance of contextual factors as triggers of placebo and nocebo effects in musculoskeletal pain. |
| Q26798430 | Deconstructing chronic low back pain in the older adult--Step by step evidence and expert-based recommendations for evaluation and treatment part III: Fibromyalgia syndrome |
| Q64067737 | Does Sex/Gender Play a Role in Placebo and Nocebo Effects? Conflicting Evidence From Clinical Trials and Experimental Studies |
| Q37549342 | Evaluating Evidence for the Role of Sleep in Fibromyalgia: A Test of the Sleep and Pain Diathesis Model |
| Q60910013 | Incidence of Placebo Adverse Events in Randomized Clinical Trials of Targeted and Immunotherapy Cancer Drugs in the Adjuvant Setting: A Systematic Review and Meta-analysis |
| Q38815321 | Increasing uncertainty in CNS clinical trials: the role of placebo, nocebo, and Hawthorne effects |
| Q34311226 | Nocebo as a potential confounding factor in clinical trials for Parkinson's disease treatment: a meta‐analysis |
| Q30596803 | Nocebo effect in randomized clinical trials of antidepressants in children and adolescents: systematic review and meta-analysis. |
| Q50616272 | Nocebo effects and psychotropic drug action |
| Q42376620 | Nocebo effects in clinical studies: hints for pain therapy |
| Q92510498 | Nocebo in Biosimilars and Generics in Neurology: A Systematic Review |
| Q37970944 | Nocebo in Headaches: Implications for Clinical Practice and Trial Design |
| Q38736906 | Nocebo in motor neuron disease: systematic review and meta-analysis of placebo-controlled clinical trials |
| Q58561333 | Nocebos in rheumatology: emerging concepts and their implications for clinical practice |
| Q35387933 | Nonspecific adverse events in knee osteoarthritis clinical trials: a systematic review |
| Q46040914 | Progress in European neurology 2012-2013. |
| Q85366029 | Q-No: a questionnaire to predict nocebo in outpatients seeking neurological consultation |
| Q59789438 | Rapid overview of systematic reviews of nocebo effects reported by patients taking placebos in clinical trials |
| Q38055026 | The nocebo effect: a clinicians guide |
| Q38120620 | The nocebo effect: patient expectations and medication side effects |
| Q96306721 | The role of the Nocebo effect in the use of biosimilars in routine rheumatology clinical practice |
| Q38972857 | Types, frequencies, and burden of nonspecific adverse events of drugs: analysis of randomized placebo-controlled clinical trials. |
Search more.